- Alcon Vivity Registry continues to demonstrate excellent
outcomes with AcrySof IQ Vivity and AcrySof IQ Vivity Toric, the
first and only PCIOL+ with wavefront-shaping technology
- World-renowned surgeons will present new registry data at
#ESCRS2023, including data on rates of visual
disturbances1,2
- Registry monitored 900+ cataract patients post-surgery,
including those with certain mild comorbidities
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, today revealed final data from
its Vivity® Registry Study, which monitored real-world patient
experiences for up to 12 months post cataract surgery with
implantation of either AcrySof® IQ Vivity® or AcrySof® IQ Vivity®
Toric presbyopia-correcting intraocular lens (PCIOL). Data from
more than 900 cataract patients demonstrated sustained clinical
performance, high patient satisfaction and reduced dependence upon
spectacles (glasses). Evidence also suggested that AcrySof® IQ
Vivity® can be used successfully in a broad range of patients,
providing surgeons and patients with additional treatment
options.
“Since its introduction, AcrySof® IQ Vivity® has been a
disruptive technology—and an innovation we are very proud of as a
company. Vivity® is a first-of-its kind, non-diffractive extended
depth of focus IOL built with our proprietary X-WAVETM technology,
which stretches and shifts light without splitting it,” said Sunil
Vasanth, VP, Europe Surgical Franchise, Alcon. “Our real-world
registry data gives surgeons the confidence that Vivity’s
performance is sustained over time. This data is also important as
it includes patients with common mild comorbidities like glaucoma,
dry eye and retinopathy/maculopathy.”
The Vivity® Registry Study3 was a multicentre, ambispective,
non-comparative, open-label, non-interventional registry study
conducted across 41 sites from eight (8) countries: Australia,
Belgium, Germany, New Zealand, the Netherlands, Portugal, Spain and
the United Kingdom. Researchers concluded that:3
- Three-quarters of patients reported no difficulty with their
sight for activities in everyday life∞
- Most patients (92%) reported they were satisfied with their
sight‡
- More than 91% of patients reported no halos, glares or
starbursts† (common visual disturbances that come from splitting
the light in a diffractive IOL)
- Excellent binocular distance and intermediate uncorrected
visual acuity was observed, with mean Snellen visual acuity values
of 20/20 and 20/25, respectively
- More than 78% and 88% of patients reported they no longer
needed to use glasses to see at arm’s length and far away,
respectively§
These results and additional data are being discussed in 11
sessions with world-renowned surgeons at the 41st Congress of the
European Society of Cataract and Refractive Surgeons (ESCRS),
currently underway in Vienna, Austria. For a full overview of
relevant abstracts, please visit MyAlconatESCRS.com.
AcrySof® IQ Vivity®, a non-diffractive IOL, uses Alcon’s
proprietary Wavefront-Shaping X-WAVETM technology, a
next-generation optical principle that stretches and shifts light
without splitting it.2 As a result, it fulfils an unmet medical
need to provide excellent distance, intermediate and functional
near vision (e.g., for close-up daily activities such as using a
mobile device), while maintaining low visual disturbances.2
Vision is at the top of people’s minds as they get older—and
surgeons can make a difference
According to a new Global Alcon Survey, vision ties with
mobility as the second most important quality of ageing (83%), with
only memory scoring higher at 84%.4,* For people already diagnosed
with cataracts, vision is the most important concern when it comes
to ageing. According to the survey, cataract patients report they
have an improvement in quality of life post-surgery, including 81%
of patients who received any PCIOL. Additionally, 69% of all people
surveyed, including those who have not been diagnosed with
cataracts, would feel liberated without their glasses. Of those
diagnosed with cataracts and awaiting surgery, 3 in 4 reported that
they would be willing to pay for a lens that eliminates the need
for spectacles.4
Vision plays a powerful role in empowering people as they age.
AcrySof® IQ Vivity® can help to meet patient demands and
expectations related to performance, quality of life and spectacle
independence.
AcrySof® IQ Vivity® and AcrySof® IQ Vivity® Toric may not be
approved in all markets; please reach out to your Alcon Rep for
questions about availability in your local market. Please refer to
relevant products DFU or Operator’s manuals for complete list of
indications, contraindications and warnings.
This content is intended for Healthcare Professionals (HCPs)
only. Please note that product related promotion of Medical Devices
to non-HCPs may be subject to restrictions based on local rules and
regulations.
About the AcrySof® IQ Vivity®
IOL
The non-diffractive AcrySof® IQ Vivity® Extended Vision
Posterior Chamber Intraocular Lens Model DFT015 (referred to as
AcrySof® IQ Vivity® IOL) is a UV-absorbing and blue light filtering
foldable intraocular lens (IOL). This IOL, compared to a monofocal
IOL, provides an extended range of vision from distance to near
without increasing the incidence of visual disturbances.
Potential side effects: As with any surgery, there is an
implicit risk, whether or not the IOL is implanted. The
complications of the IOL implantation surgery ranges from minor
side effects (usually temporary) to serious complications. Patients
with previous illnesses or disorders (such as chronic infections of
the eye or eyelids, or diabetes) may present a higher risk of
complications. Temporary surgical complications include, but are
not limited to, reactions to medications such as irritation or mild
allergic response, bleeding, redness, itching of the eye,
sensitivity to light, swelling, corneal edema (swelling of the
cornea), problems with the iris, cell growth in the IOL, and an
increase temporary eye pressure. There is a small risk of needing
further surgical treatment (such as IOL replacement implanted by a
different one or surgery to improve vision) after the implantation
of the initial IOL.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 25,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
References
- AcrySof® IQ Vivity® Extended Vision IOL DFU.
- Bala et al. Multicountry clinical outcomes of a new
nondiffractive presbyopia-correcting IOL. J Cataract Refract Surg
2022; 48:136–143.
- Reus NJ, Kooijman M, Perez-Vives C. Overall Visual Outcomes
from a Real-world Study of Presbyopia-correcting IOLs in a Large
Population. Presented at the European Society of Cataract and
Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept, 2023; Vienna,
Austria.
- Alcon Cataract Survey [REF-21516].
+Presbyopia Correcting Intraocular Lens ∞CATQUEST 9SF, patients
were asked: Do you have difficulty with the activities because of
your sight? If so, to what extent? ‡Subject satisfaction was
evaluated with the Catquest 9SF Questionnaire. Statistic refers to
‘very’ or ‘fairly’ satisfied. †Visual disturbances were evaluated
by asking open, non-prompted questions about visual experience.
§IOLSAT: In the past 7 days, how often did you need to wear
eyeglasses to see? *The Alcon Eye on Cataract survey was conducted
between March and April 2023 in Australia, Brazil, China, Germany,
India, Italy, Japan, Spain, South Korea and the United States, and
set out to evaluate vision and cataract insights among the world’s
rapidly aging population. Survey participants totaled 7,331,
including 1,826 pre- and post-cataract surgery patients aged 50+
who had received their diagnosis within the last five years (both
monofocal and multifocal intraocular lens recipients), and 5,505
people aged 50+ who had not been diagnosed with cataract(s) and who
had not undergone surgery.
Connect with us on Facebook LinkedIn
X
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230908619997/en/
Investor Relations Allen
Trang + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Cara
Jones-Faye + 41 79 93 3811 (Geneva) Cara.Jones_Faye@Alcon.com
Alcon (NYSE:ALC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Alcon (NYSE:ALC)
Gráfica de Acción Histórica
De May 2023 a May 2024